Cargando…

Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: A meta-analysis

BACKGROUND: Inflammation and cancer are closely related to each other. As a parameter that can reflect inflammation and host immune reaction, elevated blood neutrophil to lymphocyte ratio (NLR) has been confirmed to be correlated with poor prognosis in a variety of cancers. However, this remains con...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xu, Qu, Jing-Kun, Zhang, Jia, Yan, Yan, Zhao, Xi-Xi, Wang, Ji-Zhao, Qu, Hang-Ying, Liu, Lin, Wang, Jian-Sheng, Duan, Xiao-Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690700/
https://www.ncbi.nlm.nih.gov/pubmed/29137007
http://dx.doi.org/10.1097/MD.0000000000008101
_version_ 1783279661263880192
author Liu, Xu
Qu, Jing-Kun
Zhang, Jia
Yan, Yan
Zhao, Xi-Xi
Wang, Ji-Zhao
Qu, Hang-Ying
Liu, Lin
Wang, Jian-Sheng
Duan, Xiao-Yi
author_facet Liu, Xu
Qu, Jing-Kun
Zhang, Jia
Yan, Yan
Zhao, Xi-Xi
Wang, Ji-Zhao
Qu, Hang-Ying
Liu, Lin
Wang, Jian-Sheng
Duan, Xiao-Yi
author_sort Liu, Xu
collection PubMed
description BACKGROUND: Inflammation and cancer are closely related to each other. As a parameter that can reflect inflammation and host immune reaction, elevated blood neutrophil to lymphocyte ratio (NLR) has been confirmed to be correlated with poor prognosis in a variety of cancers. However, this remains controversial in breast cancer. Thus, we performed this updated meta-analysis to further clarify whether high NLR could be a predictor of survival in breast cancer patients. METHODS: We searched on PubMed Database and Cochrane Library. Overall survival (OS), disease-free survival (DFS), and cancer-specific survival were used as outcome events, and hazard ratio (HR) was chosen as the parameter to evaluate the correlation. RESULT: Eighteen eligible studies were involved in this meta-analysis. The synthesized analysis demonstrated that elevated NLR was associated with poor DFS [HR = 1.72, 95% confidence interval (95% CI) = 1.30–2.27], OS (HR = 1.87, 95% CI = 1.41–2.48), and cancer-specific survival (HR = 2.09, 95% CI = 1.04–4.21). The correlation was stronger in triple-negative breast cancer (TNBC) (OS: HR = 2.58, 95% CI = 1.63–4.06; DFS: HR = 3.51, 95% CI = 1.97–6.24). CONCLUSION: Higher NLR was correlated to poor prognosis of breast cancer patients. As a clinical parameter that we can easily obtain, NLR might be a potential predictor in patients’ survival to assist with physicians’ treatment decisions.
format Online
Article
Text
id pubmed-5690700
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-56907002017-11-28 Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: A meta-analysis Liu, Xu Qu, Jing-Kun Zhang, Jia Yan, Yan Zhao, Xi-Xi Wang, Ji-Zhao Qu, Hang-Ying Liu, Lin Wang, Jian-Sheng Duan, Xiao-Yi Medicine (Baltimore) 5750 BACKGROUND: Inflammation and cancer are closely related to each other. As a parameter that can reflect inflammation and host immune reaction, elevated blood neutrophil to lymphocyte ratio (NLR) has been confirmed to be correlated with poor prognosis in a variety of cancers. However, this remains controversial in breast cancer. Thus, we performed this updated meta-analysis to further clarify whether high NLR could be a predictor of survival in breast cancer patients. METHODS: We searched on PubMed Database and Cochrane Library. Overall survival (OS), disease-free survival (DFS), and cancer-specific survival were used as outcome events, and hazard ratio (HR) was chosen as the parameter to evaluate the correlation. RESULT: Eighteen eligible studies were involved in this meta-analysis. The synthesized analysis demonstrated that elevated NLR was associated with poor DFS [HR = 1.72, 95% confidence interval (95% CI) = 1.30–2.27], OS (HR = 1.87, 95% CI = 1.41–2.48), and cancer-specific survival (HR = 2.09, 95% CI = 1.04–4.21). The correlation was stronger in triple-negative breast cancer (TNBC) (OS: HR = 2.58, 95% CI = 1.63–4.06; DFS: HR = 3.51, 95% CI = 1.97–6.24). CONCLUSION: Higher NLR was correlated to poor prognosis of breast cancer patients. As a clinical parameter that we can easily obtain, NLR might be a potential predictor in patients’ survival to assist with physicians’ treatment decisions. Wolters Kluwer Health 2017-11-10 /pmc/articles/PMC5690700/ /pubmed/29137007 http://dx.doi.org/10.1097/MD.0000000000008101 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle 5750
Liu, Xu
Qu, Jing-Kun
Zhang, Jia
Yan, Yan
Zhao, Xi-Xi
Wang, Ji-Zhao
Qu, Hang-Ying
Liu, Lin
Wang, Jian-Sheng
Duan, Xiao-Yi
Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: A meta-analysis
title Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: A meta-analysis
title_full Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: A meta-analysis
title_fullStr Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: A meta-analysis
title_full_unstemmed Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: A meta-analysis
title_short Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: A meta-analysis
title_sort prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: a meta-analysis
topic 5750
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690700/
https://www.ncbi.nlm.nih.gov/pubmed/29137007
http://dx.doi.org/10.1097/MD.0000000000008101
work_keys_str_mv AT liuxu prognosticroleofpretreatmentneutrophiltolymphocyteratioinbreastcancerpatientsametaanalysis
AT qujingkun prognosticroleofpretreatmentneutrophiltolymphocyteratioinbreastcancerpatientsametaanalysis
AT zhangjia prognosticroleofpretreatmentneutrophiltolymphocyteratioinbreastcancerpatientsametaanalysis
AT yanyan prognosticroleofpretreatmentneutrophiltolymphocyteratioinbreastcancerpatientsametaanalysis
AT zhaoxixi prognosticroleofpretreatmentneutrophiltolymphocyteratioinbreastcancerpatientsametaanalysis
AT wangjizhao prognosticroleofpretreatmentneutrophiltolymphocyteratioinbreastcancerpatientsametaanalysis
AT quhangying prognosticroleofpretreatmentneutrophiltolymphocyteratioinbreastcancerpatientsametaanalysis
AT liulin prognosticroleofpretreatmentneutrophiltolymphocyteratioinbreastcancerpatientsametaanalysis
AT wangjiansheng prognosticroleofpretreatmentneutrophiltolymphocyteratioinbreastcancerpatientsametaanalysis
AT duanxiaoyi prognosticroleofpretreatmentneutrophiltolymphocyteratioinbreastcancerpatientsametaanalysis